Cytokinetics Q2 net loss $198.8M; MYQORZO revenue $25M; ACACIA-HCM positive

CYTOKINETICS INC

Total revenues $28.6M (Q2 2025: $66.8M) including $25.3M MYQORZO net product revenue; no license/milestone revenue in Q2 2026.
Net loss $198.8M ($1.50/share) vs $134.4M ($1.12) in Q2 2025; R&D $97.8M, SG&A $104.4M.
Cash, equivalents and investments $1.7B (up from $1.1B at Mar 31, 2026) after $760.1M net from public offering of 11.3M shares at $71.
ACACIA-HCM (nHCM) met dual primary endpoints; supplemental NDA for aficamten in nHCM expected Q4 2026.
FY 2026 GAAP combined R&D+SG&A guidance raised to $860M-$890M from $830M-$870M; over 700 prescribers, ~1,500 patients dispensed MYQORZO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.